

N0745, Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma

Status Change – July 30, 2009

NOTICE OF STATUS CHANGE

This study is temporarily suspended to patient accrual effective Thursday, July 30, 2009. Patient entry will not be permitted after July 30 at 3:30 CST until further notification is issued.

The study is closed per protocol design for the initial evaluation of dose levels and adverse events in the Phase I portion of the trial.

The study will re-open to patient accrual at the completion of the evaluation and notification of the re-opening will be distributed at that time.

Please retain this notice with the protocol.